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Abstract 
Purpose: To investigate the effectiveness of an ethanol extract of Phyllanthus niruri against hepatitis B 
viral (HBV) infection in human HepG2/C3A cells.  
Methods: An ellagic acid-rich ethanol fraction was obtained from P. niruri (Euphorbiaceae) by extraction 
and thin-layer chromatography. The anti-HBV activity of the fraction was evaluated in vitro against 
HepG2/C3A cells. The physicochemical characteristics of the fraction were assessed by nuclear 
magnetic resonance (1H and 12C-NMR).  
Results: The isolated active compound showed a half-maximal inhibitory concentration (IC50) of 120 
µg/mL. Ellagic acid had no effect on HBV DNA replication at the concentrations evaluated, and did not 
inhibit the reproduction of HBV. However, the ethanol fraction inhibited the growth of HBV-infected 
HepG2/C3A cells. 
Conclusion: The findings suggest that the ethanol fraction of P. niruri inhibits HBV, and that the active 
component is not ellagic acid. 
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Hepatitis B virus (HBV) is a hepatotropic virus 
and the causative agent of hepatitis B. HBV 
infection may lead to hepatocellular carcinoma 
(HCC) and cirrhosis [1]. HBV infection may be 
symptomless in many people during the initial 
stages. Globally, HBV is responsible for 0.5–1 
million deaths annually. Although a considerable 
portion of carriers have varied level of hepatocyte 
obliteration, the infection can lead to HCC or 
cirrhosis [2]. More than 300 million individuals 
are infected with HBV, which is thus considered 
a pandemic [3]. Treatments for HBV infection 
include standard and pegylated interferon-alpha 
and nucleoside analogues such as entecavir, 
lamivudine and adefovir. However, current 
therapies are unable to eradicate HBV. 
Development of drug resistance and reactivation 
of viral replication can occur even when 
treatment is successful [4]. The aim of therapies 
for HBeAg-positive and -negative individuals 
should be long-term eradication of HBV DNA, 
with an endpoint of hepatitis B surface antigen 
(HBsAg) seroconversion [5]. 
 
Phyllanthus niruri L. (Euphorbiaceae) is a 
medicinal herb distributed in South Asia. In 
traditional medicine, the plant has long been 
used as a hepatoprotectant and for treatment of 
hepatitis B [6]. Current HBV therapies can result 
in moderate-to-severe side effects, development 
of resistance to HBV expansion, or limited 
efficacy in only a subset of HBV-infected patients 
[7]. Despite the availability of numerous antiviral 
drugs, a number of issues remain, such as 
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limited efficacy, dose-dependent side-effects, 
and drug resistance. Therefore, more-effective 
anti-HBV drugs are urgently needed. Despite 
their potential, few natural herbs have been 
evaluated in a systematic manner. The goals of 
HBV treatment are to prevent development of 
HCC and cirrhosis, regulate alkaline 
transaminase (ALT) levels, suppress viral 
replication, and reduce the liver damage in 
HBeAg-negative as well as with HBeAg-positive 
individuals [8]. 
 
It has been reported that water extract of P. niruri 
inhibits cellular DNA polymerase activity during 
HBV replication [9]. A considerable proportion of 
untreated newborns of mothers who are long-
term HBeAg carriers become infected, and 90 % 
become long-term carriers [10]. The secretory 
non-particulate form of HBeAg is not necessary 
for HBV replication or infection. The immune 
system responds to the presence of HBeAg and 
suppresses infection [11].  
 
The plant Phyllanthus niruri (also known as 
Phyllanthus amarus) exhibits anti-HBV activity 
and has long been used to treat jaundice in 
southern India [12]. P. niruri belongs to the family 
Euphorbiaceae and can be used to treat kidney 
stones [13] and disorders of the gastrointestinal 
and genitourinary tracts [14].  
 
In this study, we isolated and characterized 
ellagic acid from P. niruri and assessed its effect 
on HBV-infected HepG2/C3A cells as a potential 
agent to prevent the development and 
progression of hepatitis virus and HCC in chronic 




Evaluation of physicochemical properties 
 
Cary 60 UV-Vis and 660 FTIR (together with 
potassium bromide) spectrophotometers (both 
from Agilent Technologies (Santa Clara, 
California, United States) were used to monitor 
UV-visible and infrared spectra, respectively. The 
acquired spectra were subjected to high-
throughput mass spectrometry (electrospray 
ionization MS).  
 
Bruker nuclear magnetic resonance (NMR) 
spectroscopy at 400 MHz, utilized to obtain the 
1H and 12C NMR spectra in CDCl3. 
Electrothermal’s melting point apparatus (Bibby 
Scientific Limited, Staffordshire, UK) was utilized 
to assess the melting point. Thin-layer 
chromatography was conducted on silica gel 60 
F254 plates (250 μm). 
 
Isolation and purification of an anti-HBV 
compound from P. niruri 
 
Five hundred grams of dried P. niruri plant mass 
were subjected to aqueous extraction at 37 °C 
for 3 h. The extract was filtrated twice under low 
pressure at 40 °C (Figure 1). The supernatant 
was resolved on a gel column using a 
CHCl3/MeOH gradient twice. Fraction #12 was 
then separated on a silica gel column (70/10/1 
CHCl3/MEOH/H2O) at low pressure. The 
resulting brown-colored powder was subjected to 
preparative HPLC using a mobile phase of 
acetonitrile/1 % formic acid (10/90 to 45/55 % 
gradients). Anti-HBV activity was evaluated as an 
increase in antigen secretion by HepG2/C3A 
cells (Figure 2). Extracellular HBeAg was 
detected using an ELISA kit. 
 
Anti-HBV activity assay 
 
HepG2/C3A cells were plated on 24-well flat-
bottom culture plates at 3  105/mL. Following 
incubation for 24 h, test compounds were applied 
to the plates.  
 
The compounds were dissolved in dimethyl 
sulfoxide (DMSO) to 1, 2, 4, 8, 16, 32, 64 and 
128 µg. The highest concentration was 2.5 
µg/mL, which did not affect HepG2/C3A cells. 
HBsAg levels were evaluated by enzyme 
immunoassay (Sigma-Aldrich Shanghai Trading 
Co Ltd, Shanghai, China). The reactions were 
assayed at a wavelength of 492 nm using the 
CLARIOstar® High-Performance Multimode 
Microplate Reader. Inhibition (%) was evaluated 
in comparison with DMSO as in Eq 1: 
 
Reduction (%) = {(1−As/Ab)}100 
 
where As and Ab are the absorbance of test 
sample and blank, respectively. 
 
Data are presented as the means of three 
replicates. Activity was classified as follows: 20 – 
35 % as weak, 30 – 50 % as medium, 50 – 65 % 
as strong, and > 65 % as very strong. Cell 
damage was assessed by aspartate 
transaminase (AST) assay (Abnova Corporation, 
Taipei, Taiwan). AST values of > 25 IU/L were 




For the initial assessment of HBV reproduction, 
secreted levels of HBeAg from HepG2/C3A cells 
following treatment of P. niruri extracts or ellagic 
acid were evaluated by ELISA (Hepatitis B 
Antigen ELISA kit; DRG International Inc., 
Springfield, NJ, USA). 
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Assessment of HBV DNA levels 
 
Cells were lysed in 0.5 mL lysis buffer (2 % 
sarkosyl, 7 % 2-mercaptoethanol, 4 M guanidine 
isothiocyanate) and then washed for 1 h in 1 mM 
EDTA, 50 mM Tris (pH 8.0) using a 
micro-dialysis device (Life Technologies, 
Gaithersburg, MD, USA). Next, Proteinase K was 
added, removed using chloroform and phenol 
and resuspended in ethanol as described 
previously [17,18]. Cells cultured in 10-cm-
diameter dishes were disrupted in degenerative 
buffer (6 mL), and DNA was extracted as 
described elsewhere [25]. DNA (10 μg/lane) was 
digested by EcoRI, separated by electrophoresis 
in 1 % agarose gels, and transferred to 
nitrocellulose membranes. DNA fragments were 
radiolabeled with [32P] dCTP 32P dCTP, using a 
nick-translation kit (Invitrogen, Carlsbad, CA, 
USA) as per manufacturer’s instructions, and 
then hybridized with a specific probe (specific 
activity 3–5 × 108 dpm/μg). Post-washing and 
hybridization were performed as described 
previously [9]. 
 
HBV polymerase assay 
 
The medium from propagating HepG2/C3A 
cells was collected and treated with 
polyethylene glycol 8000 (PEG 8000) to 
precipitate nucleocapsids. Nucleocapsids 
were isolated from HBV-infected cells and 
assayed for endogenous polymerase activity. 
HBV polymerase activity was monitored by 
measuring the incorporation of [ɑ-32P]-
labeled deoxynucleotide triphosphate (dNTP) 
into acid-precipitated products. Each 40 µL 
assay reaction consisted of 100 mmol/L Tris 
(pH 7.5), 10 mmol/L MgCl2, 0.6 U/µL RNasin, 
5 % glycerol, 0.2 µg/µL activated calf thymus 
DNA, 100 µmol/L unlabeled dNTPs, [ɑ-32P]-
labeled dNTP (approximately 100 Ci/mmol), 
and ellagic acid at various concentrations.  
 
To determine the inhibition constants for 
penciclovir triphosphate (dGTP substrate 
analog), adefovir diphosphate (dATP 
substrate analog), and lamivudine 
triphosphate (dCTP substrate analog), [a-
32P]-labeled dGTP, [ɑ-32P]-labeled dATP, and 
[ɑ-32P]-labeled dCTP were used, 
respectively. Five microliters of HBV 
polymerase (~ 0.1 µg) were added to initiate 
the reaction. Twelve-microliter aliquots were 
removed at 0–20 minutes and transferred 
onto Whatman 3MM paper discs. The paper 
discs were washed three times in 5 % 
trichloroacetic acid plus 1 % sodium 
pyrophosphate and once in 95 % ethanol. 
The incorporated radioactivity was measured 
using liquid scintillation counting (LSC) 
(Amersham Bioscience, Uppsala, Sweden). 
 
Computation of half-maximal inhibitory 
concentrations (IC50) 
 
Intracellular encapsidated HBV DNA was 
extracted and subjected to gel blot analysis. 
The IC50 of each drug was determined as the 
concentration resulting in a 50 % decrease in 
the viral DNA level compared with that of 
untreated cells. 
 
Statistical analysis  
 
Data are shown as means ± standard deviation 
(SD, n = 3). IC50 values were computed using 
Origin Lab version 18.0 software (Origin Lab Inc., 
Guangzhou, China). Students’ non-paired t-test 
was used to compare factors between the 
sample and solvent control. A value of P < 0.005 




Anti-HBV activity of extract fractions 
 
Figure 1 shows the antiviral activity of the various 
fractions of the plant extract. 
 
Attributes of hepatitis B-reducing elements 
 
The physicochemical properties of components 
with anti-HBV activity are shown in Table 1. 
Crystals of the active component were yellow in 
color. The component had a molecular weight of 
302 Da, and infrared spectroscopy showed 
absorption at 3380, 1720, 1690, and 1610 cm−1, 
indicating the presence of phenolic hydroxyl, α-
byron C=O, and benzenoid C=C groups. These 
results together with other findings (melting point, 
UV spectra, Rf, and solubility) indicated that the 
active component is ellagic acid, C14H6O8. The 
1H NMR spectrum of ellagic acid has a singlet at 
δ 7.47, which was associated with two protons at 
C-5 and C-5 (Table 2). The 13C NMR spectrum of 
ellagic acid exhibited quinone carbonyl carbons 
at 168.60 and 145.86, showing C-2+C-2, C-4+C-
4, and C-3+C-3, which were associated with δ 
157.58 and δ 149.01. In addition, δ 119.73 and 
121.79 were assigned to four carbons at C-5, C-
5 and C-1, C-1, and δ 117.3 was assigned to C-
6, C-6. The 13C NMR data thus supported 
identification of the active component as ellagic 
acid. 
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Figure 2: Anti-HBV activity of extract fractions 
 
Table 1: Physicochemical properties of ellagic 
acid 
 
Appearance Yellow powder 
Melting point (°C) 300‒360 
Molecular formula C14H6O8 
FAM-MS (m/z) 301 [M‒H]− 
UV, λmax (nm) 300 
IR, vmax (nm) 3380, 1720, 1690 and 1610 
Rf value (TLC) 0.67 
Solubility DMSO, ethanol and methanol 
 
Effect of ellagic acid on HBeAg secretion  
 
Fraction #12 exhibited dose-dependent toxicity 
towards HepG2/C3A cells (Figures 3 and 4). 
Ellagic acid was incapable of increasing HBV 
polymerase activity. PEG 8000 precipitated virion 
particles with four deoxyribonucleic was used to 
observed anti-polymerase functions of ellagic 
acid. Lamivudine 3TC triphosphate was used as 
the positive control (Figure 5). 
 
We assessed whether the ellagic acid from P. 
niruri extract is responsible for the reduction in 
HBV polymerase activity. Ellagic acid at 10, 20, 
40, and 60 µg/mL did not inhibit HBV replication 
(lanes 5–8) (Figure 6), unlike the positive control, 
3TC (0.1, 1.0, and 10.0 mM) (lanes 2–4). 
Furthermore, 0.2 mM 3TC inhibited HBV 




Chronic HBV infection can lead to development 
of cirrhosis and HCC, which increases the risk of 
death. The FDA has approved two drugs to treat 
HBV infection; however, both show poor efficacy 
and various side effects [20,21].  
 
Medicinal plants have long been used to treat 
various illnesses worldwide. HBV infects millions 
of people worldwide and causes a severe, 
transmittable disease of the liver. The 
pharmaceutical industry is endeavoring to 
discover a natural anti-HBV agent. Therefore, it 
is important to explore phytochemicals as a new 
source of drugs. However, data on the antiviral 
activity of medicinal plants are limited. 
Phyllanthus species have long been used as 
herbal remedies for HBV infection. 
 
Table 2: 1H and 13C NMR spectral data for ellagic 







1 121.790 - 
2 145.867 - 
3 149.015 - 
4 157.58 - 
5 119.734 7.47(s) 
6 - 7.47(s) 
7 117.161 - 
8 168.601 - 
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Figure 5: Analysis of HepG2/C3A cell-derived DNA following treatment with ellagic acid. Ten 
micrograms of EcoRI-digested cellular DNA were loaded per lane. DNA blots were probed with [32P]-
labeled HBV cDNA probes. A 1 kb DNA ladder was used to estimate product size. Lane 1 (control), 
DMSO. Lanes 2–4, 3TC (0.1, 1.0, and 10 mM). Lanes 5–8, ellagic acid (10, 20, 40, and 60 µg/mL) 
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Figure 6: Effect of ellagic acid on HBeAg and HBsAg secretion by HepG2/C3A cells. Ellagic acid 
inhibited HepG2/C3A HBeAg secretion. HBsAg and HBeAg levels in lysates from HepG2/C3A cells 
treated with ellagic acid (1–5, 7, 10, 15, and 20 µg/mL) 
 
In this study, P. niruri extract exhibited anti-HBV 
activity in HepG2/C3A cells. 
 
Ellagic acid, found in berry fruits, has 
components with anti-inflammatory, anti-fibrotic, 
and antioxidant activities. Ellagic acid was shown 
to reduce HBeAg production by HepG2 2.2.15 
cells [22].  
 
Ellagic acid has potent antioxidant activity. 
Moreover, ellagic acid has growth-inhibiting and 
apoptosis-inducing cytotoxic effects on cancer 
cells, including leukemic, pancreatic, breast, 
neuroblastoma, colon, prostate, tongue, and 
osteogenic sarcoma cells. Ellagic acid-treated 
cells show apoptosis, increased caspase 3/7 
activities, activation of caspase 3, and cleavage 
of poly-ADP ribose polymerase [23]. Although 
ellagic acid possesses potent activity against 
human DNA polymerases β, η, ι, and κ in vitro, 
our data did not indicate significant inhibition [24]. 
This indicates that viral reproduction is not 
suppressed by ellagic acid. As HBV is a DNA 
virus, reverse transcriptase inhibitors may be a 





A potential anti-HBV agent, ellagic acid, was 
isolated from the medicinal plant P. niruri, and its 
physicochemical properties were characterized. 
The isolated compound exerted a cytotoxic effect 
against HepG2/C3A cells. Ellagic acid did not 
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